I don't think so in this case. There hasn't been any run-up in stock price. In fact the stock performance has been pretty disappointing; there certainly hasn't been any irrational or even rational exuberance in the price. Just ask the institutional investors that bought in at 16. This stock has never gotten the attention or valuation it deserves for developing this breakthrough technology that will save many lives, improve the quality of many lives, and truly advance cancer therapy. So, IMO we are in for a long-awaited, well deserved and lasting higher price level for Immunogen. Congrats and appreciation to the fine scientists and doctors responsible.